title: [Antitumor effects of liposome-entrapped carboplatin (Lipo-CBDCA) after intraperitoneal administration in rats bearing carcinomatous peritonitis].
abstract: We examined the distribution of Lipo-CBDCA after intraperitoneal administration and antitumor effects in rats. The serum levels of platinum in Lipo-CBDCA were lower than in free-CBDCA intraperitoneal or intravenous administration at 15 and 30 min. after administration. After 3 hours, Lipo-CBDCA showed higher levels of serum platinum than free-CBDCA. These data showed the slow release of Lipo-CBDCA. The antitumor effects of Lipo-CBDCA were studied in rats with peritoneal dissemination due to AH 130 tumors. Intraperitoneal treatment with Lipo-CBDCA prolonged the life span significantly compared with Lipo-CBDCA. No side effects of chemotherapy were found in the liver, kidney, spleen or small intestine. A gastric cancer patient suffering from carcinomatous peritonitis with remarkable ascites was treated with Lipo-CBDCA intraperitoneally. After several injections of Lipo-CBDCA, the ascites disappeared completely and the CEA level of ascites decreased dramatically. These results indicate that intraperitoneal chemotherapy with Lipo-CBDCA may be more effective than free-CBDCA to manage carcinomatous peritonitis, and may be therapeutically useful without toxic side effects.
authors.affiliation: First Dept. of Surgery, Medical School, Nagoya City University.
authors.forename: I
authors.initials: I
authors.lastname: Mizuno
authors.forename: T
authors.initials: T
authors.lastname: Yasui
authors.forename: H
authors.initials: H
authors.lastname: Takeyama
authors.forename: M
authors.initials: M
authors.lastname: Ishikawa
authors.forename: J
authors.initials: J
authors.lastname: Terada
authors.forename: N
authors.initials: N
authors.lastname: Mohri
authors.forename: T
authors.initials: T
authors.lastname: Ueda
authors.forename: N
authors.initials: N
authors.lastname: Sumita
authors.forename: K
authors.initials: K
authors.lastname: Kobayashi
authors.forename: Y
authors.initials: Y
authors.lastname: Akamo
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001202:Ascitic Fluid / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D016190:Carboplatin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004337:Drug Carriers; D006801:Humans; D007263:Infusions, Parenteral; D008081:Liposomes; D008297:Male; D008875:Middle Aged; D010538:Peritonitis / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D051381:Rats; D013274:Stomach Neoplasms / Q000150:complications
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D008081:Liposomes; D016190:Carboplatin